Testosterone Replacement Therapy in Hypogonadal Men: Assessing Benefits, Risks, and Best Practices

References

• Allan CA, McLachlan RI. Age-related changes in testosterone and the role of replacement therapy in older men. J Clin Endocrinol (Oxj). 2004; 60(6): 653–670.
   PubMed Web of Science ®Google Scholar
• The Food and Drug Administration. Updates: Skin Patch Replaces Testosterone. FDA Consumer Magazine. Published January/February 1996. http://www.fda.gov/fdac/departs/196_upd.html.
   Google Scholar
• Hall, SA, Araujo AB, Esche GR, et al. Treatment of symptomatic androgen deficiency: results from the Boston Area Community Survey. Arch Intern Med. 2008; 168(10): 1070–1076.
   PubMedGoogle Scholar
• Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007; 92(11): 4241–4247.
   PubMed Web of Science ®Google Scholar
• Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab. 2004; 89(11): 5462–5468.
   PubMed Web of Science ®Google Scholar
• Dandona P, Dhindsa S, Chaudhuri A, Bhatia V, Topiwala S, Mohanty P. Hypogonadotrophic hypogonadism in type 2 diabetes, obesity and the metabolic syndrome. Curr Molec Med. In Press.
   Google Scholar
• Ohl DA, Quallich SA. Clinical hypogonadism and androgen replacement therapy: an overview. UrolNurs. 2006; 26(4): 253–259,269.
   Google Scholar
• Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. J Am Board Fam Pract. 2004; 17(1): 59–67.
   PubMedGoogle Scholar
• Casaburi R, Bhasin S, Cosentino L, et al. Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004; 170(8): 870–878.
   PubMed Web of Science ®Google Scholar
• Blackman MR, Sorkin JD, Münzer T, et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA. 2002; 288(18): 2282–2292.
   PubMed Web of Science ®Google Scholar
• Crawford BA, Liu PY, Kean MT, Bleasel JF, Handelsman DJ. Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab. 2003; 88(7): 3167–3176.
   PubMed Web of Science ®Google Scholar
• Ferrando AA, Sheffield-Moore M, Paddon-Jones D, Wolfe RR, Urban RJ. Differential anabolic effects of testosterone and amino acid feeding in older men. J Clin Endocrinol Metab. 2003; 88(1): 358–362.
   PubMed Web of Science ®Google Scholar
• Ferrando AA, Sheffield-Moore M, Yeckel CW, et al. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab. 2002; 282(3): E601–E607.
   PubMed Web of Science ®Google Scholar
• Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sei Med Sci. 2001; 56(5): M266–M272.
   PubMed Web of Science ®Google Scholar
• Katznelson L, Robinson MW, Coyle CL, Lee H, Farrell CE. Effects of modest testosterone supplementation and exercise for 12 weeks on body composition and quality of life in elderly men. Eur J Endocrinol. 2006; 155(6): 867–875.
   PubMed Web of Science ®Google Scholar
• Münzer T, Harman SM, Hees P, et al. Effects of GH and/or sex steroid administration on abdominal subcutaneous and visceral fat in healthy aged women and men. J Clin Endocrinol Metab. 2001; 86: 3604–3610.
   PubMed Web of Science ®Google Scholar
• Page ST, Amory JK, Bowman FD, et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab. 2005; 90(3); 1502–1510.
   PubMed Web of Science ®Google Scholar
• Reid IR, Wattie DJ, Evans MC, Stapleton JP. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med. 1996; 156(11): 1173–1177.
   PubMedGoogle Scholar
• Schroeder ET, Singh A, Bhasin S, et al. Effects of an oral androgen on muscle and metabolism in older, community-dwelling men. Am J Physiol Endocrin Metab. 2003; 284(1): E120–E128.
   PubMed Web of Science ®Google Scholar
• Sih R, Morley JE, Kaiser FE, Perry HM 3rd, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab. 1997; 82(6): 1659–1660.
   PubMed Web of Science ®Google Scholar
• Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab. 1999; 84(8): 2647–2653.
   PubMed Web of Science ®Google Scholar
• Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab. 2003; 88(6): 2673–2681.
   PubMed Web of Science ®Google Scholar
• Svartberg J, Aasebo U, Hjalmarsen A, Sundsfjord J, Jorde R. Testosterone treatment improves body composition and sexual function in men with COPD, in a 6-manth randomized controlled trial. Respir Med. 2004; 98(9): 906–913.
   PubMed Web of Science ®Google Scholar
• Svartberg J, Agledahl I, Figenschau Y, Sildnes T, Waterloo K, Jorde R. Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res. 2008; 20(4): 378–387.
   PubMed Web of Science ®Google Scholar
• Wittert GA, Chapman IM, Haren MT, Mackintosh S, Coates P, Morley JE. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol A Biol Sci Med Sci. 2003; 58(7): 618–625.
   PubMed Web of Science ®Google Scholar
• Committee on Assessing the Need for Clinical Trials of Testosterone Replacement Therapy. Testosterone and Aging: Clinical Research Directions. Institute of Medicine. Washington, DC: National Academies Press, 2003.
   Google Scholar
• Miner MM, Seftel AD. Testosterone and aging: what have we learned since the Institute of Medicine report and what lies ahead? Int J Clin Pract. 2007; 61 (4): 622–632.
   PubMed Web of Science ®Google Scholar
• Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf). 2005; 63(3): 280–293.
   PubMed Web of Science ®Google Scholar
• Amory JK, Watts NB, Easley KA, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab. 2004; 89(2): 503–510.
   PubMed Web of Science ®Google Scholar
• Christmas C, O'Connor KG, Harman SM, et al. Growth hormone and sex steroid effects on bone metabolism and bone mineral density in healthy aged women and men. J Gerontol A Biol Sei Med Sci. 2002; 57(1): M12–M18.
   PubMed Web of Science ®Google Scholar
• Hall GM, Larbre JP, Spector TD, Perry LA, DaSilva JA. A randomized trial of testosterone therapy in males with rheumatoid arthritis. Br J Rheumatol. 1996; 35(6): 568–573.
   PubMedGoogle Scholar
• Meier C, Liu PY, Ly LP, et al. Recombinant human chorionic gonadotropin but not dihydrotestosterone alone stimulates osteoblastic collagen synthesis in older men with partial age-related androgen deficiency. J Clin Endocrinol Metab. 2004; 89(6): 3033–3041.
   PubMed Web of Science ®Google Scholar
• Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab. 1999; 84(6): 1966–1972.
   PubMed Web of Science ®Google Scholar
• Tracz MJ, Sideras K, Boloña ER, et al. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab. 2006; 91 (6): 2011–2016.
   PubMed Web of Science ®Google Scholar
• Orwoll E, Lambert LC, Marshall LM, et al. Endogenous testosterone levels, physical performance, and fall risk in older men. Arch Intern Med. 2006; 166(19): 2124–2131.
   PubMedGoogle Scholar
• Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male. 2003; 6(1): 1–7.
   PubMedGoogle Scholar
• Chung T, Kelleher S, Liu PY, Conway AJ, Kritharides L, Handelsman DJ. Effects of testosterone and nandrolone on cardiac function: a randomized, placebo-controlled study. Clin Endocrinol (Oxf). 2007; 66(2): 235–245.
   PubMed Web of Science ®Google Scholar
• English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation. 2000; 102(6): 1906–1911.
   PubMedGoogle Scholar
• Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006; 154(6): 899–906.
   PubMed Web of Science ®Google Scholar
• Kenny AM, Prestwood KM, Gruman CA, Fabregas G, Biskup B, Mansoor G. Effects of transdermal testosterone on lipids and vascular reactivity in older men with low bioavailable testosterone levels. J Gerontol A Biol Sei Med Sci. 2002; 57(7): M460-M465.
   Web of Science ®Google Scholar
• Maikin CJ, Pugh PJ, Jones RD, West JN, Jones TH, Channer KS. Testosterone improves functional capacity and symptoms in men with heart failure. Heart. 2004; 90: 446–447.
   PubMedGoogle Scholar
• Mårin P, Holmäng S, Gustafsson C, et al. Androgen treatment of abdominally obese men. Obes Res. 1993; 1 (4): 245–251.
   PubMedGoogle Scholar
• Mårin P, Holmäng S, Jönsson L, et al. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord. 1992; 16(12): 991–997.
   PubMed Web of Science ®Google Scholar
• Mårin P. Testosterone and regional fat distribution. Obes Res. 1995; 3 Suppl 4: 609S-612S.
   Google Scholar
• Simon D, Charles MA, Lahlou N, et al. Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone: a 3-month randomized placebo-controlled trial. Diabetes Care. 2001; 24: 2149–2151.
   PubMed Web of Science ®Google Scholar
• Snyder PJ, Peachey H, Berlin JA, et al. Effect of transdermal testosterone treatment on serum lipid and apolipoprotein levels in men more than 65 years of age. Am J Med. 2001; 111(4): 255–260.
   PubMed Web of Science ®Google Scholar
• Uyanik BS, Ari Z, Giimiis B, Yigitoglu MR, Arslan T. Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men. A placebo controlled study. Jpn Heart J. 1997; 38(1): 73–82.
   PubMedGoogle Scholar
• Shabsigh R, Katz M, Yan G, Makhsida N. Cardiovascular issues in hypogonadism and testosterone therapy. Am J Cardiol. 2005; 96(12B): 67M-72M.
   Web of Science ®Google Scholar
• Wu FC, von Eckardstein A. Androgens and coronary artery disease. EndocrRev. 2003; 24(2): 183–217.
   PubMed Web of Science ®Google Scholar
• Anderson RA, Bancroft J, Wu FC. The effects of exogenous testosterone on sexuality and mood of normal men. J Clin Endocrinol Metab. 1992; 75(6): 1503–1507.
   PubMed Web of Science ®Google Scholar
• Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf). 2003; 58(5): 632–638.
   PubMed Web of Science ®Google Scholar
• Benkert O, Witt W, Adam W, Leitz A. Effects of testosterone undecanoate on sexual potency and the hypothalamic-pituitary-gonadal axis of impotent males. Arch Sex Behav. 1979; 8(6): 471–479.
   PubMed Web of Science ®Google Scholar
• Cavallini G, Caracciolo S, Vitali G, Modenini F, Biagiotti G. Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology. 2004; 63(4): 641–646.
   PubMed Web of Science ®Google Scholar
• Kunelius P, Lukkarinen O, Hannuksela ML, Itkonen O, Tapanainen JS. The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. J Clin Endocrinol Metab. 2002; 87(4): 1467–1472.
   PubMed Web of Science ®Google Scholar
• Park NC, Yan BQ, Chung JM, Lee KM. Oral testosterone undecanoate (Andriol) supplement therapy improves the quality of life for men with testosterone deficiency. Aging Male. 2003; 6(2): 86–93.
   PubMedGoogle Scholar
• Schiavi RC, White D, Mandeli J, Levine AC. Effect of testosterone administration on sexual behavior and mood in men with erectile dysfunction. Arch Sex Behav. 1997; 26(3): 231–241.
   PubMed Web of Science ®Google Scholar
• Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol. 2004; 172(2): 658–663.
   PubMed Web of Science ®Google Scholar
• Shabsigh R. Testosterone therapy in erectile dysfunction and hypogonadism. J Sex Med. 2005; 2(6): 785–792.
   PubMed Web of Science ®Google Scholar
• Boloña ER, Uraga MV, Haddad RM, et al. Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007; 82(1): 20–28.
   PubMed Web of Science ®Google Scholar
• Isidori AM, Giannetta E, Gianfrilli D, et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf). 2005; 63(4): 381–394.
   PubMed Web of Science ®Google Scholar
• Miner MM, Kuritzky L. Erectile dysfunction: a sentinel marker for cardiovascular disease in primary care. Cleve Clin J Med. 2007; 74 Suppl 3: S30-S37.
   Google Scholar
• Cherrier MM, Asthana S, Plymate S, et al. Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology. 2001; 57(1): 80–88.
   PubMed Web of Science ®Google Scholar
• Janowsky JS, Chavez B, Orwoll E. Sex steroids modify working memory. J Cogn Neurosci. 2000; 12(3): 407–4.
   PubMed Web of Science ®Google Scholar
• Janowsky JS, Oviatt SK, Orwoll ES. Testosteron´ influences spatial cognition in older men. Behav Neurosci. 1994; 108(2): 325–332.
   PubMed Web of Science ®Google Scholar
• Kenny AM, Fabregas G, Song C, Biskup B, Bellantonio S. Effects of testosterone on behavior, depression and cognitive function in older men with mild cognitive loss. J Gerontol A Biol Sei Med Sci. 2004; 59(1): 75–78.
   PubMed Web of Science ®Google Scholar
• Kenny AM, Bellantonio S, Gruman CA, Acosta RD, Prestwood KM. Effects of transdermal testosterone on cognitive function and health perception in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci. 2002; 57(5): M321-M325.
   Web of Science ®Google Scholar
• Pope HG Jr, Cohane GH, Kanayama G, Siegel AJ, Hudson JI. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatiy. 2003; 160(1): 105–111.
   PubMed Web of Science ®Google Scholar
• Reddy P, White CM, Dunn AB, Moyna NM, Thompson PD. The effect of testosterone on health-related quality of life in elderly males—a pilot study. J Clin Pharm Ther. 2000; 25(6): 421–426.
   PubMed Web of Science ®Google Scholar
• Seidman SN, Spatz E, Rizzo C, Roose SP. Testosterone replacement therapy for hypogonadal men with major depressive disorder: a randomized, placebo-controlled clinical trial. J Clin Psychiatry. 2001; 62(6): 406–412.
   PubMed Web of Science ®Google Scholar
• Rhoden EL, Morgentaler A. Risks of testosterone replacement therapy and recommendations for monitoring. New Engl J Med. 2004; 350(5): 482–492.
   PubMed Web of Science ®Google Scholar
• Endogenous Hormones, Prostate Cancer Collaborative Group; Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008; 100(3): 170–183.
   PubMedGoogle Scholar
• Carpenter WR, Robinson WR, Godley PA. Getting over testosterone: postulating a fresh start for etiologic studies of prostate cancer. J Natl Cancer Inst. 2008; 100(3): 158–159.
   PubMedGoogle Scholar
• International Society for the Study of the Aging Male (ISSAM). Free and bioavailable testosterone calculator. Ghent, Belgium: University Hospital of Ghent,. Belgium, http://www.issam.ch/freetesto.htm
   Google Scholar
• Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006; 91(6): 1995–2010.
   PubMed Web of Science ®Google Scholar
• Wang C, Nieschlag E, Swerdloff RS, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lenenfeld B, Morales A, Morley JE, Schulman C, Thompson I, Weidner W, Wu F. ISA, ISSAM, EAU, EAA, and ASA Recommendations for the Investigation, Treatment, and Monitoring of Late-Onset Hypogonadism in Males. [Published online ahead of print September 4, 2008]. J Androl.
   Google Scholar
• Lunenfeld B, Saad F, Hoesl CE. ISA, ISSAM, and EAU recommendations for the investigation, treatment, and monitoring of late-onset hypogonadism in males: scientific background and rationale. Aging Male. 2005; 8(2): 59–74.
   PubMedGoogle Scholar
• Rosen RC. Optimizing testosterone replacement therapy in hypogonadal men. Contemporary Urology. 2007; 19(5): 30–34.
   Google Scholar
• Seftel AD, Mack RJ, Secrest AR, Smith TM. Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning. J Androl. 2004; 25(6): 963–972.
   PubMedGoogle Scholar
• Amory JK, Page ST, Bremmer WJ. Oral testosterone in oil: pharmacokinetic effects of 5alpha reduction by finasteride or dutasteride and food intake in men. J Androl. 2006; 27(1): 72–78.
   PubMedGoogle Scholar
• Saad F, Kamischke A, Yassin A, et al. More than eight years' hands-on experience with the novel long-acting parenteral testosterone undecanoate. Asian J Androl. 2007; 9(3): 291–217.
   PubMed Web of Science ®Google Scholar
• Bagatell CJ. Bremner WJ. Androgen and progestagen effects on plasma lipids. Prog Cardiovasc Dis. 1995; 38(3): 255–271.
   PubMed Web of Science ®Google Scholar
• Yoshida EM, Erb SR, Scudamore CH, Owen DA. Severe cholestasis and jaundice secondary to an esterified testosterone, a non-C17 alkylated anabolic steroid. J Clin Gastroenterol. 1994; 18(3): 268–270.
   PubMed Web of Science ®Google Scholar
• Harman SM. Testosterone in older men after the Institute of Medicine Report: where do we go from here? Climateric. 2005; 8(2): 124–135.
   PubMed Web of Science ®Google Scholar
• Liverman CT, Blazer DG, eds. Testosterone and Aging: Clinical Research Directions. Washington, DC: The National Academies Press, 2004.
   Google Scholar
• Morley JE, Charlton E, Patrick P, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism. 2000; 49(9): 1239–1242.
   PubMed Web of Science ®Google Scholar